Log in
Enquire now
‌

Q-state Biosciences, Inc. SBIR Phase I Award, August 2019

A SBIR Phase I contract was awarded to Q-State Biosciences in August, 2019 for $585,093.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1684973
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
Q-State Biosciences
Q-State Biosciences
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R44MH121169-010
Award Phase
Phase I0
Award Amount (USD)
585,0930
Date Awarded
August 8, 2019
0
End Date
June 30, 2020
0
Abstract

Project SummaryMaintaining the appropriate balance of excitationEvsinhibitionIin the nervous system is essential for normal brain functionas disruptions in E I balance are associated with disorders such as autism spectrum disorderASDschizophreniaand seizuresDevelopment of therapeutics for ASD and schizophrenia has lagged due to their multifactorial etiology and challenges in modeling relevant biology in scalable in vitro assaysThe Optopatch platform recently developed at Q State Bioscienceswhich uses engineered optogenetic proteinscustom microscopesand softwaremakes it possible to simultaneously stimulateblue lightand recordred lightelectrical activity fromneurons withmillisecond temporal resolutionsingle cell spatial resolution and high signal to noise ratioIn addition to measurements of intrinsic excitabilitypatterned blue light can be used to probe synaptic connections by stimulating a subset of neurons and recording postsynaptic potentialsPSPsin all remaining cellsThe Optopatch assayswhich record signals in individual neuronscan be paired with fluorescent labels of inhibitory neurons to identify compounds that differentially affect signaling in excitatory and inhibitory cells and would be expected to shift the E I balanceIn Phase I of this projectwe propose toadapt the established Q State assays for intrinsic excitability and synaptic transmission to measure the E I balance andvalidate these assays using tool compounds and gene knockdowns expected to shift the E I balanceIn Phase IIwe propose toscreen annotated compound librariesconfirm that proteins targeted by compounds in the library can modulate the E I balanceandvalidate that identified targets can also shift the E I balance in human stem cell derived neurons and in rodent brain sliceThe identified protein targets will serve as a starting point for drug discoveryand identified FDAapproved compounds may be repurposed for new indicationsThe suite of tools developed here will pave a new path for developing E I modulating therapeutics for treating complex neurological disorders such as autism and schizophrenia Project Narrative The balance between excitatoryEand inhibitoryIsignaling in the brain is essential for healthy brain functiondisruptions in this delicate balance have been linked to multiplepoorly treated neurological disorders including depressionschizophreniaautismand epilepsyQ State has developed engineered proteins and custom microscopes that enable us to rapidly record excitatory and inhibitory signaling in thousands of neurons grown in a dishWe will screen a library of small molecules for compounds capable of tuning the E I balance and characterize the compounds to determine their likelihood of being developed into effective therapeutics for neurological conditions

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Q-state Biosciences, Inc. SBIR Phase I Award, August 2019

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.